The National Comprehensive Cancer Network and the National Cancer Institute agree that patients with CML treated with TKIs currently should be monitored for levels of transcription of the BCR-ABL. The guidelines recommend testing BCR-ABL at diagnosis to establish a basic level of BCR-ABL, every three months while the patient seems to respond to therapy and every 6-3 months after a patient with complete cytogenetic response . If a patient has a rising level of BCR-ABL transcripts , the guidelines call for evaluating the compliance of patients, repeat the test in one to three months and / or analysis ABL kinase mutation domain.The test has been widely used in MolecularMD late stage pivotal clinical trial for second-generation TKIs help demonstrate the response of the patient improved, said Jane Barlow, vice president, clinical innovation, Medco. The use of this molecular test regularly to determine whether a patient is exposed to the appropriate response to medication may help ensure better clinical outcomes for patients and reduce the cost of the overall health of the health plan.
According to the U.S. Census Bureau, the nation’s population almost doubled to 70 million in 2030. Moreover, the %age of ethnic elders will double to 40 % of the U.S. population aged 65 and over in 2050.
The current standard treatment for patients with CML is the tyrosine kinase inhibitor therapy, which showed a large and robust as an effective treatment targeted. Three TKIs have been approved by the Food and Drug Administration for first-line therapy, including imatinib , dasatinib and nilotinib .
Medco Health Solutions, Inc. and MolecularMD Corp. has announced the launch of a program of personalized medicine for chronic myeloid . Through this program, Medco will provide patients with a diagnosis of CML, a molecular test known as qRT-PCR BCR-ABL to monitor the disease
The test program offers the LMC is the tenth in the DNA directly from Medco growing portfolio of personalized medicine. Other tests in the program is to contribute to determining the safety or efficacy of drugs such as Coumadin , Plavix , Nolvadex , Ziagen and Selzentry , and biometric checks.
Currently, 300 customers representing more than 10 million members are enrolled in Medco personalized medicine programs.